8-K current report · filed Nov 9, 2026

Axogen, Inc. (AXGN) 8-K Current Report: November 9, 2026

Item 7.01Item EX-99.1AXGN overview

Short answer

Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Axogen posted a corporate presentation on November 9, 2026 for use in analyst and investor discussions.

Axogen, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Axogen posted a corporate presentation on November 9, 2026 for use in analyst and investor discussions
  • Presentation available through Axogen’s investor-relations website and Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Corporate presentation outlines a prostate nerve reconstruction launch using Avance, expanding Axogen beyond its existing peripheral-nerve markets
  • Estimated addressable market: approximately 110,000 annual cases and $754 million TAM at approximately $7,000 weighted ASP
  • Clinical experience includes more than 220 reconstructed patients, with approximately 80% exceeding expected erectile-function recovery
  • More than 95% of reported patients regained continence, supporting potential quality-of-life and surgeon-adoption benefits
  • Key execution risks: clinical validation, regulatory processes, reimbursement, market access and surgeon adoption

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Axogen, Inc. 8-K filings

Get the next AXGN 8-K as it lands

Follow AXGN for push alerts, or ask the research agent what this filing means.